Delgocitinib: First Approval
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Delgocitinib, a janus kinase (JAK) inhibitor, is being developed by Japan Tobacco for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. The JAK family of tyrosine kinases plays an important role in mediating the biological effects of several inflammatory cytokines, e.g. IL-4, IL-13 and IL-31, which are elevated in patients with atopic dermatitis. Delgocitinib inhibits all members of the JAK family [JAK1, JAK2, JAK3 and tyrosine kinase 2]. Topical delgocitinib (Corectim®) is approved in Japan for the treatment of atopic dermatitis. This article summarizes the milestones in the development of delgocitinib leading to this first approval for the treatment of adults with atopic dermatitis. Clinical development of the topical formulation is also underway for alopecia areata, chronic hand eczema, discoid lupus erythematosus, inverse psoriasis and atopic dermatitis in several countries worldwide. Clinical development of an oral formulation of delgocitinib is also underway in Japan for the treatment of autoimmune disorders and hypersensitivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After successful phase III studies224,225, topical delgocitinib ointment was approved in 2020 for moderate to severe AD in Japan226.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [226]
Citations
Cites
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.010 · Cited by 1,277
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224 · cited 3×
“skin cancer and lymphoma), although a causal relationship has not been established [3].”
BackgroundAmano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., Dainichi, T., Honda, T., Otsuka, A., Kimoto, Y., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.051 · Cited by 259
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242
Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016
Saeki, H., Nakahara, T., Tanaka, A., Kabashima, K., Sugaya, M., Murota, H., Ebihara, T., Kataoka, Y., Aihara, M., Etoh, T., et al. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13392 · Cited by 172
Nakagawa, H., Nemoto, O., Igarashi, A., & Nagata, T. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16014 · Cited by 145
[CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF ATOPIC DERMATITIS 2018].
Ebihara, T. (2021) · PubMed · doi:10.15036/arerugi.70.1186 · Cited by 119
Tanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., et al. (2015) · Inflammation Research · doi:10.1007/s00011-014-0782-9 · Cited by 111
Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Oda, M., Kabashima, K., & Nagata, T. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.004 · Cited by 108
Worm, M., Bauer, A., Elsner, P., Mahler, V., Molin, S., & Nielsen, T. S. S. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18469 · Cited by 107
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
A Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
“Delgocitinib (Figure 22) is a pan-JAK inhibitor that was approved for atopic dermatitis in 2020 in Japan [69].”
BackgroundInfluentialJAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I.-H., Chung, W.-H., Wu, P.-C., & Chen, C.-B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 329
Metadata
- Authors
- Dhillon, S.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Dhillon, Sohita
- Venue
- Drugs
- Published
- 2020-03-12
- Volume
- 80
- Issue
- 6
- Pages
- 609-615
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3010985734
- Cited by
- 126
- References
- 14
- Citations by year
- 2026: 17 · 2025: 14 · 2024: 18 · 2023: 20 · 2022: 26 · 2021: 25 · 2020: 6
- FWCI
- 14.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- delgocitinib, JAK inhibitors, atopic dermatitis, topical formulation, drug approval, alopecia areata, chronic hand eczema, discoid lupus erythematosus, inverse psoriasis, autoimmune disease, hypersensitivity, IL-4, IL-13, IL-31, inflammatory cytokines, oral dosage forms
- MeSH terms
- Janus Kinase Inhibitors, Animals, Autoimmune Diseases, Humans, Hypersensitivity, Molecular Conformation, Pyrroles, Drug Approval, Janus Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delgocitinib: First Approval. https://app.cochat.ai/papers/10.1007/s40265-020-01291-2
- The paper
- Dhillon, S. (2020). Delgocitinib: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01291-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.